What is it about?
This publication focuses on a formulation to target melanoma cells specifically by making use of antigens expressed specifically on these cells. This formulation is validated and assessed by various techniques including SDS gel, ELISA, Flow cytometry and confocal microscopy.
Featured Image
Why is it important?
Two novel TCR-like antibodies are used to couple to liposomes. These antibodies are against MAGE A1 antigen that is uniquely expressed by melanoma cells. This strategy can be a step towards personalized medicines and decrease the toxicity of drug in question.
Read the Original
This page is a summary of: Targeting melanoma with immunoliposomes coupled to anti-MAGE A1 TCR-like single-chain antibody, International Journal of Nanomedicine, March 2016, Dove Medical Press,
DOI: 10.2147/ijn.s96123.
You can read the full text:
Contributors
The following have contributed to this page
